The (AAT)n repeat of the cannabinoid CB1 receptor gene influences disease progression in relapsing multiple sclerosis

• Published in: Multiple sclerosis Vol. 17; no. 3; pp. 281 - 288
• Main Authors: Rossi, Silvia, Buttari, Fabio, Studer, Valeria, Motta, Caterina, Gravina, Paolo, Castelli, Maura, Mantovani, Vilma, De Chiara, Valentina, Musella, Alessandra, Fiore, Stefania, Masini, Silvia, Bernardi, Giorgio, Maccarrone, Mauro, Bernardini, Sergio, Centonze, Diego
• Format: Journal Article
• Language: English
• Published: London, England SAGE Publications 01.03.2011; Sage Publications Ltd
• Subjects: Adult; Chi-Square Distribution; Disability Evaluation; Disease Progression; Female; Gene Frequency; Genetic Predisposition to Disease; Heterozygote; Homozygote; Humans; Immunosuppressive Agents - therapeutic use; Italy; Male; Multiple Sclerosis, Relapsing-Remitting - diagnosis; Multiple Sclerosis, Relapsing-Remitting - drug therapy; Multiple Sclerosis, Relapsing-Remitting - genetics; Phenotype; Polymorphism, Genetic; Receptor, Cannabinoid, CB1 - genetics; Risk Assessment; Risk Factors; Severity of Illness Index; Treatment Outcome; Trinucleotide Repeats; Young Adult; Italy; neurodegeneration; BREMS; progression index; excitotoxicity; CNR1; treatment failure
• ISSN: 1352-4585; 1477-0970; 1477-0970
• DOI: 10.1177/1352458510388680

Background: Genetic and pharmacological inactivation of cannabinoid CB1 receptors (CB1Rs) exacerbates disease course in experimental autoimmune encephalomyelitis, suggesting that CB1Rs might play a role in the neurodegenerative damage associated with multiple sclerosis (MS). Objectives: To see whether CNR1 gene polymorphism could influence disease progression in relapsing–remitting MS. Methods: The genotype of 350 patients for the number of AAT repeats was characterized and correlation studies were performed with measures of disease severity and progression. Results: MS patients with the homozygous genotype for long AAT repeats in the CNR1 gene had more severe disease and higher risk of progression. These subjects had significantly higher scores on both the progression index and the MS severity scale. Furthermore, the percentage of patients with MS functional composite score progression or Bayesian Risk Estimate for MS (BREMS) score ≥2 (considered at very high risk of secondary progression) was significantly higher in the AAT long group than in the short group, while the frequency of patients with BREMS score ≤−0.63 (very likely to remain progression-free) was not significantly different between the two groups, although lower in the long group. Finally, the frequency of patients prescribed a second-line treatment was significantly higher among subjects of the AAT long group, providing a further, indirect indication of higher disease severity. Conclusions: The results of the present investigation point to CB1R as an important modulator of disease severity in relapsing MS subjects.